Randomized Controlled Trial of Moderate-Intensity Rosuvastatin With Ezetimibe Combination Therapy Versus High-Intensity Rosuvastatin on Progression of Coronary Atherosclerotic Plaque

Inclusion Criteria: * Subject must be at least 19 years of age * Subject with suspected ischemic heart disease undergoing coronary angiography and have intermediate coronary artery stenosis (30-70% by visual estimation) whose revascularization was deferred based on invasive physiologic assessment using fractional flow reserve (\>0.80) or intravascular ultrasound (minimum lumen area\> 4mm2) * Subject can verbally confirm understandings of risks, benefits and treatment alternatives of receiving statin or ezetimibe and he/she or his/her legally authorized representative provides written informed consent prior to any study related procedure. Exclusion Criteria: * Subject has calculated creatinine clearance \<30 mL/min or dialysis within 30 days. * Subject has active liver disease or persistent unexplained serum transaminase elevations (x2 x upper limit of normal \[ULN\]). * Subject requires the following concomitant medications: cyclosporine, danazol, niacin, fibrates as concomitant medications * Subject requires any of the potent CYP3A4 inhibitors, itraconazole, ketoconazole, erythromycin, clarithromycin, and telithromycin, HIV protease inhibitors, nefazodone, probucol, resins, and any investigational drugs. * Subject has an allergy/sensitivity to any statin, ezetimibe, and/or their excipients. * Subject with history of myopathy or family history of myopathy * Untreated hypothyroidism * Subject has a history of alcohol and/or drug abuse. * Subject is a pregnant or lactating w…